
Expansol6%+0.9%
Incepta Pharmaceuticals Ltd.
Hydroxyethyl Starch + Sodium Chloride is a colloid intravenous fluid indicated for the treatment and prophylaxis of hypovolemia (low circulating blood volume) when treatment with crystalloid…
Hydroxyethyl Starch + Sodium Chloride is a colloid intravenous fluid indicated for the treatment and prophylaxis of hypovolemia (low circulating blood volume) when treatment with crystalloid solutions alone is considered insufficient.
Hydroxyethyl Starch + Sodium Chloride does not replace red blood cells or plasma coagulation factors and is not intended as a substitute for blood transfusion when blood products are clinically required.
Important restriction: Current safety data show that Hydroxyethyl Starch + Sodium Chloride should generally not be used in critically ill patients (including those with sepsis), in patients with pre-existing renal impairment, or in burn injury patients, because of an increased risk of death and severe kidney injury in these populations. Use in these settings is considered inappropriate and not evidence-supported.
| Indication | Adult Dose | Pediatric Dose |
|---|---|---|
| Acute hypovolemia (non-critically ill, e.g. surgical/trauma blood loss) | Individualized based on blood loss, hemodynamic status, and hemodilution effect; total daily dose commonly limited to a maximum of approximately 30-33 mL/kg body weight per day depending on the specific product concentration/substitution grade used, per local product labeling. | Individualized and weight-based (commonly cited around 15-25 mL/kg/day in published pediatric experience), used cautiously and only when clearly indicated; exact dosing should follow the specific product's approved labeling. |
Hydroxyethyl Starch + Sodium Chloride is administered by slow intravenous infusion, with the initial 10-20 mL infused slowly while the patient is observed closely for early signs of an anaphylactoid/hypersensitivity reaction. The infusion rate and total volume must be individualized to the patient's hemodynamic response, ongoing fluid losses, and hemodilution, and should be given at the lowest effective dose for the shortest possible duration.
Renal impairment: Hydroxyethyl Starch + Sodium Chloride should not be used in patients with significant renal impairment or those on renal replacement therapy (see Contraindications).
Hepatic impairment: Use with caution and enhanced monitoring in patients with liver disease; avoid in severe hepatic impairment (see Contraindications).
Adverse effects reported with Hydroxyethyl Starch + Sodium Chloride include:
Patients should seek urgent medical attention for signs of severe allergic reaction, unusual bleeding, decreased urine output, or breathing difficulty during or after infusion of Hydroxyethyl Starch + Sodium Chloride.
Hydroxyethyl Starch + Sodium Chloride is contraindicated in:
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.